Close Menu


The self-contained, cartridge-based test runs on the firm's GeneXpert system.

The study is being conducted in Sierra Leone by the University of Oxford.

Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.

The firm has also created a qPCR-based Staphylococcus aureus resistance gene assay with a run time of three minutes.

Biocartis will initially test the device against synthetic virus samples and subsequently run trials in West Africa.

Other collaborators include the Institute Pasteur, the Organization of International Visitors of the USA, and Thermo Fisher Scientific.

Recurring revenues drove growth during the quarter, while instrument revenues also improved year over year.

The test would allow healthcare workers to differentiate Ebola from other diseases that mimic the virus, a trait which presented problems during the recent crisis in West Africa. 

The team tracked down several hundred SNPs in the Ebola genome, including mutations that could alter the effectiveness of treatments targeting certain virus sequences.

Trends included expanding test menus and a possible tipping point for point-of-care.


Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.